214 related articles for article (PubMed ID: 35671079)
1. Integrase inhibitor-based regimens are related to favorable systemic inflammatory index and platecrit scores in people living with HIV (PLWH) up to 2 years.
Şahin EA; Mavi D; Kara E; Sönmezer MÇ; İnkaya AÇ; Ünal S
Postgrad Med; 2022 Aug; 134(6):635-640. PubMed ID: 35671079
[TBL] [Abstract][Full Text] [Related]
2. Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
Tse J; Prajapati G; Zhao X; Near AM; Kumar PN
Curr Med Res Opin; 2023 Sep; 39(9):1237-1246. PubMed ID: 37480288
[TBL] [Abstract][Full Text] [Related]
3. Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy.
Fabbiani M; Borghetti A; Squillace N; Colafigli M; Taramasso L; Lombardi A; Rossetti B; Ciccullo A; Colella E; Picarelli C; Berruti M; Latini A; Montagnani F; Sambo M; Di Biagio A; Gori A; Di Giambenedetto S; Bandera A
J Acquir Immune Defic Syndr; 2021 Jan; 86(1):119-127. PubMed ID: 33306566
[TBL] [Abstract][Full Text] [Related]
4. Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study.
Masiá M; Padilla S; Barber X; Sanchis M; Terol G; Lidón F; Gutiérrez F
Medicine (Baltimore); 2016 Mar; 95(11):e3108. PubMed ID: 26986155
[TBL] [Abstract][Full Text] [Related]
5. Weight gain after antiretroviral therapy initiation in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
Zhao X; Prajapati G; Tse J; Near AM; Kumar PN
Curr Med Res Opin; 2023 Jul; 39(7):997-1006. PubMed ID: 37334707
[TBL] [Abstract][Full Text] [Related]
6. CD4/CD8 Ratio Recovery Among People Living With HIV Starting With First-Line Integrase Strand Transfer Inhibitors: A Prospective Regional Cohort Analysis.
Han WM; Avihingsanon A; Rajasuriar R; Tanuma J; Mundhe S; Lee MP; Choi JY; Pujari S; Chan YJ; Somia A; Zhang F; Kumarasamy N; Tek Ng O; Gani Y; Chaiwarith R; Pham TN; Do CD; Ditangco R; Kiertiburanakul S; Khol V; Ross J; Jiamsakul A;
J Acquir Immune Defic Syndr; 2023 Feb; 92(2):180-188. PubMed ID: 36625858
[TBL] [Abstract][Full Text] [Related]
7. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
Bourgi K; Rebeiro PF; Turner M; Castilho JL; Hulgan T; Raffanti SP; Koethe JR; Sterling TR
Clin Infect Dis; 2020 Mar; 70(7):1267-1274. PubMed ID: 31100116
[TBL] [Abstract][Full Text] [Related]
8. Inflammation markers and the risk of hypertension in people living with HIV.
Ou-Yang H; Fu HY; Luo Y; Xu ZY; Liu J; Gao R; Duan JY; Mao YC; Li HJ; Du YR
Front Immunol; 2023; 14():1133640. PubMed ID: 37025998
[TBL] [Abstract][Full Text] [Related]
9. The effects of ART on the dynamics of lipid profiles in Chinese Han HIV-infected patients: comparison between NRTI/NNRTI and NRTI/INSTI.
Liu S; Wei B; Liang W; Chen T; Deng L; Zhao M; Wan J
Front Public Health; 2023; 11():1161503. PubMed ID: 37181701
[TBL] [Abstract][Full Text] [Related]
10. Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy.
Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Huang SH; Huang YC; Su YC; Liu WC; Hung CC
Int J Infect Dis; 2021 Apr; 105():147-151. PubMed ID: 33592339
[TBL] [Abstract][Full Text] [Related]
11. Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database.
Ruzicka DJ; Kuroishi N; Oshima N; Sakuma R; Naito T
BMC Infect Dis; 2019 Jun; 19(1):505. PubMed ID: 31182050
[TBL] [Abstract][Full Text] [Related]
12. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study.
Serrano-Villar S; Martínez-Sanz J; Ron R; Talavera-Rodríguez A; Fernández-Felix BM; Herrera S; Muriel A; Fanjul F; Portilla J; Muñoz J; Amador C; de Zárraga MA; Vivancos MJ; Moreno S;
Lancet HIV; 2020 Aug; 7(8):e565-e573. PubMed ID: 32763219
[TBL] [Abstract][Full Text] [Related]
13. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort.
Álvarez H; Rava M; Martínez C; Portilla J; Peraire J; Rivero A; Cervero M; Mariño A; Poveda E; Llibre JM;
HIV Med; 2022 Sep; 23(8):825-836. PubMed ID: 35234328
[TBL] [Abstract][Full Text] [Related]
14. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
[TBL] [Abstract][Full Text] [Related]
15. Effects of antiretroviral therapy on proprotein convertase subtilisin/kexin 9: focus on lipids, inflammation and immunovirological parameters.
Bianconi V; Schiaroli E; Pirro M; Cardaci S; Busti C; Mannarino MR; Baldelli F; Francisci D
HIV Med; 2020 Sep; 21(8):512-522. PubMed ID: 32496664
[TBL] [Abstract][Full Text] [Related]
16. Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients?
Milanés-Guisado Y; Gutiérrez-Valencia A; Muñoz-Pichardo JM; Rivero A; Trujillo-Rodriguez M; Ruiz-Mateos E; Espinosa N; Roca-Oporto C; Viciana P; López-Cortés LF
J Antimicrob Chemother; 2020 Jan; 75(1):200-207. PubMed ID: 31617904
[TBL] [Abstract][Full Text] [Related]
17. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
Norwood J; Turner M; Bofill C; Rebeiro P; Shepherd B; Bebawy S; Hulgan T; Raffanti S; Haas DW; Sterling TR; Koethe JR
J Acquir Immune Defic Syndr; 2017 Dec; 76(5):527-531. PubMed ID: 28825943
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatment.
Mocroft A; Neesgard B; Zangerle R; Rieger A; Castagna A; Spagnuolo V; Antinori A; Lampe FC; Youle M; Vehreschild JJ; Mussini C; Borghi V; Begovac J; Duvivier C; Gunthard HF; Rauch A; Tiraboschi J; Chkhartishvili N; Bolokadze N; Wit F; Wasmuth JC; De Wit S; Necsoi C; Pradier C; Svedhem V; Stephan C; Petoumenos K; Garges H; Rogatto F; Peters L; Ryom L;
HIV Med; 2020 Oct; 21(9):599-606. PubMed ID: 32588958
[TBL] [Abstract][Full Text] [Related]
19. Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens.
Maggi P; Ricci ED; Cicalini S; Pellicanò GF; Celesia BM; Vichi F; Cascio A; Sarchi E; Orofino G; Squillace N; Madeddu G; De Socio GV; Bargiacchi O; Molteni C; Masiello A; Saracino A; Menzaghi B; Falasca K; Taramasso L; Di Biagio A; Bonfanti P
BMC Infect Dis; 2023 Apr; 23(1):227. PubMed ID: 37059996
[TBL] [Abstract][Full Text] [Related]
20. Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States.
Rebeiro PF; Emond B; Rossi C; Bookhart BK; Shah A; Caron-Lapointe G; Lafeuille MH; Donga P
J Int AIDS Soc; 2023 Jun; 26(6):e26123. PubMed ID: 37306118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
